“We are very encouraged by the recent significant acceleration in patient enrollment due to the opening of all 60 planned centers in the study and the increase in the volume of surgical procedures following the conclusion of the slower summer months,” stated Dikla Czaczkes Akselbrad, PolyPid’s (PYPD) Chief Executive Officer. “With more than 540 patients enrolled to date in SHIELD II, we look forward to the upcoming interim analysis later this quarter. Importantly, we are funded beyond this key data catalyst and, if all the warrants issued in both of our most recent private placement financings are exercised, we would be funded into 2026.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PYPD:
- PYPD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- PolyPid Announces $8.25 Million Share Sale Plan
- Craig-Hallum bullish on PolyPid, initiates with a Buy
- PolyPid initiated with a Buy at Craig-Hallum
- PolyPid announces publication in IJS on Phase 3 SHIELD I trial of D-PLEX100
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
